These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7310392)

  • 1. Predictors for improvement after electroconvulsive therapy in parkinsonian patients with on-off symptoms.
    Balldin J; Granérus AK; Lindstedt G; Modigh K; Wålinder J
    J Neural Transm; 1981; 52(3):199-211. PubMed ID: 7310392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine evidence for increased responsiveness of dopamine receptors in humans following electroconvulsive therapy.
    Balldin J; Granérus AK; Lindstedt G; Modigh K; Wålinder J
    Psychopharmacology (Berl); 1982; 76(4):371-6. PubMed ID: 6812112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolactin response as an index of dopaminergic receptor function in Parkinson's disease. Correlation with clinical findings and therapeutic response.
    Agnoli A; Baldassarre M; Ruggieri S; Falaschi P; Urso RD; Rocco A
    J Neural Transm; 1981; 51(1-2):123-34. PubMed ID: 7264625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electroconvulsive therapy in Parkinsonian patients with the "on-off" syndrome.
    Ward C; Stern GM; Pratt RT; McKenna P
    J Neural Transm; 1980; 49(1-2):133-5. PubMed ID: 7441236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind evaluation of electroconvulsive therapy in Parkinson's disease with "on-off" phenomena.
    Andersen K; Balldin J; Gottfries CG; Granérus AK; Modigh K; Svennerholm L; Wallin A
    Acta Neurol Scand; 1987 Sep; 76(3):191-9. PubMed ID: 2446463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance ECT in Parkinson's disease.
    Fall PA; Granérus AK
    J Neural Transm (Vienna); 1999; 106(7-8):737-41. PubMed ID: 10907732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of electroconvulsive therapy in Parkinson disease with residual axial symptoms partially unresponsive to L-dopa: a pilot study.
    Pintor LP; Valldeoriola F; Fernández-Egea E; Sánchez R; Rami L; Tolosa E; Muñiz A; Martí MJ; Bernardo M
    J ECT; 2012 Jun; 28(2):87-91. PubMed ID: 22531200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender but not stimulus parameters influence prolactin response to electroconvulsive therapy.
    Motreja S; Subbakrishna DK; Subhash MN; Gangadhar BN; Janakiramaiah N; Parameshwara G
    Psychoneuroendocrinology; 1997 Jul; 22(5):337-48. PubMed ID: 9279939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in serum prolactin after electroconvulsive and epileptic seizures.
    Johansson F; von Knorring L
    Eur Arch Psychiatry Neurol Sci; 1987; 236(5):312-8. PubMed ID: 2888653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of acute and repeated electroconvulsive treatment on plasma beta-endorphin, growth hormone, prolactin and cortisol secretion in depressed patients.
    Weizman A; Gil-Ad I; Grupper D; Tyano S; Laron Z
    Psychopharmacology (Berl); 1987; 93(1):122-6. PubMed ID: 2957720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ECT on the neuroendocrine response to apomorphine in severely depressed patients.
    Christie JE; Whalley LJ; Brown NS; Dick H
    Br J Psychiatry; 1982 Mar; 140():268-73. PubMed ID: 6807386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone and prolactin stimulation by Madopar in Parkinson's disease.
    Martinez-Campos A; Giovannini P; Parati E; Novelli A; Caraceni T; Müller EE
    J Neurol Neurosurg Psychiatry; 1981 Dec; 44(12):1116-23. PubMed ID: 7334406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance electroconvulsive therapy for Parkinson's disease.
    Aarsland D; Larsen JP; Waage O; Langeveld JH
    Convuls Ther; 1997 Dec; 13(4):274-7. PubMed ID: 9437571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of single and repeated electroconvulsive therapy sessions on plasma ACTH, prolactin, growth hormone and cortisol concentrations.
    Kronfol Z; Hamdan-Allen G; Goel K; Hill EM
    Psychoneuroendocrinology; 1991; 16(4):345-52. PubMed ID: 1660606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
    Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
    Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvements in both psychosis and motor signs in Parkinson's disease, and changes in regional cerebral blood flow after electroconvulsive therapy.
    Usui C; Hatta K; Doi N; Kubo S; Kamigaichi R; Nakanishi A; Nakamura H; Hattori N; Arai H
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1704-8. PubMed ID: 21605615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of depression and parkinsonism during ECT: a case study.
    Dysken M; Evans HM; Chan CH; Davis JM
    Neuropsychobiology; 1976; 2(2-3):81-6. PubMed ID: 1012451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone response to repeated electroconvulsive therapy: effects of naloxone.
    Haskett RF; Zis AP; Albala AA
    Biol Psychiatry; 1985 Jun; 20(6):623-33. PubMed ID: 2986737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Electroconvulsive treatment in parkinsonism].
    Arsland D; Larsen JP; Tandberg E
    Tidsskr Nor Laegeforen; 1993 Nov; 113(29):3564-6. PubMed ID: 8273093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.